Due to the dual role of TRIM21 in impairing dsDNA sensing in myeloid DCs and mtDNA sensing in tumour cells, pharmacological interventions targeting TRIM21 may simultaneously activate mtDNA sensing and IFN responses in both tumour cells and DCs, leading to further enhancement of the antitumour immune response. Here, IFNA1 is linked to neoplasm.